Aim: We performed acute and chronic studies in healthy and diet-induced obese animals using mouse-specific or monkey-specific dual GLP-1R/GCGR agonists to investigate their effects on food intake, body weight, blood glucose control and insulin secretion. The selective GLP-1R agonist liraglutide was used as comparator.
caemic control, the addition of glucagon receptor agonism (GCGR) appears contradictory, as the acute physiological response to glucagon is counter regulatory to the glucose-lowering action of insulin.
Glucagon exerts its hyperglycaemic effects through a transient increase of hepatic glucose production. [1] [2] [3] [4] [5] [6] However, the description of oxyntomodulin as an endogenous and naturally occurring enteroendocrine peptidic hormone, activating both GLP-1R and GCGR, inspired the development of dual GLP-1R/GCGR agonists. 7, 8 Oxyntomodulin combines the anorectic and glucose-lowering effect of GLP-1R agonists with the increased energy expenditure mediated by the GCGR. Chronic infusion of oxyntomodulin in GLP-1R knock-out mice (GLP-1R −/− ) produced a decrease in body weight, but to a lower extent as compared to wild-type (WT) mice. This revealed that the anti-obesity effect of oxyntomodulin requires activation of both GLP-1R and GCGR. 9 Stimulation of both receptors reverses diet-induced obesity (DIO) in high-fat fed mice 10 and reduces body weight in overweight and obese human subjects. 11 Recent research efforts have focused on developing dual acting GLP-1R/GCGR agonists which combine GLP-1-related reduction of appetite and food intake with glucagon-related increase in energy expenditure 12 . Pre-clinical data from rodents indicate that dual GLP-1R/GCGR agonists elicit greater weight loss when compared to selective GLP-1R agonists. 8 Similarly,
Lao et al. reported that their dual GLP-1R/GCGR agonist showed
higher weight loss in diet-induced obese rhesus monkeys and better glucose control in diabetic rhesus monkeys than GLP-1R agonist gold standard liraglutide. 13 A recent report also indicates that administration of MEDI0382, a dual GLP-1R/GCGR agonist, at toxicological doses, to lean and healthy cynomolgus monkeys led to significant reduction in body weight. 14 The impact on body weight results from a significant suppression of energy intake but may also arise from increased energy expenditure as observed in a sub-chronic study in rats, 15 in a multiple dosing study for 4 weeks in DIO mice 8 and in humans. 16 Co-administration studies in humans confirmed that the concomitant activation of GLP-1R mitigates the potential metabolic risk and hyperglycaemic impact of GCGR activation. Notably, while GCG infusion was accompanied by a rise in plasma glucose levels, coinfusion of GLP-1 and GCG led to a rapid decrease in glucose, as a result of a synergistic insulinotropic effect. 17 While resting energy expenditure was not affected by GLP-1 infusion, it rose significantly with GCG alone and to a similar extent in combination with GCG and GLP-1. In a follow-up study, GCG or GLP-1, given individually at subanorectic doses, did not reduce food intake in humans. But coinfusion at the same doses led to a significant reduction in food intake and increased energy expenditure, and protected against glucagon-induced hyperglycaemia. 18 And several studies confirm that GCG elicits thermogenic activity and significantly increases energy expenditure. 5, [19] [20] [21] We recently reported that dual GLP-1R/GCGR agonists, which are structurally based on the exendin-4 sequence, benefit from the favourable physicochemical properties of exendin-4. 22 These new dual agonists carry a fatty acid side chain on position 14 to improve half-life. In this paper, we focus on such dual agonists, with a receptor activity ratio favouring the GLP-1R to ensure proper glucose control and show the pharmacological profile in mice and obese diabetic NHP, which is, in our view, the most relevant translational model for the human situation ( Table 1) . Because of the distinct speciesdependent variation in GCGR agonist activity observed in peptides, we synthesized surrogates that were mouse-and monkey-specific dual agonists with relative GLP-1R/GCGR activity preferences similar to the human dual GLP-1R/GCGR agonist currently in clinical development (see ClinicalTrials.gov, NCT02411825). Because of the overlapping pharmacology observed following activation of GLP-1 and GCG receptors, GCGR target engagement to guide compound optimization poses an experimental challenge. The current studies were therefore designed to demonstrate the acute effects of mousespecific dual agonists compared to the reference, that is, selective GLP-1R agonist liraglutide in healthy WT and GLP-1R −/− mice. With repetitive analysis of oxygen consumption and carbon dioxide production during chronic treatment, we investigated substrate utilization and were able to differentiate between fat and carbohydrate oxidation in DIO mice. In addition to the monitoring of change in body weight and food intake, total energy expenditure (TEE) and carbohydrate (CHO) and fat oxidation (FO) were determined in the chronic setting. We further performed chronic studies in DIO nonhuman primates to evaluate efficacy of monkey-specific dual agonist on glucose control and body weight as well as to interrogate biomarkers reflecting the distinct action of the dual approach.
| MATERIALS AND METHODS

| Animals and housing conditions -mouse studies
All mouse-related experimental procedures were conducted in accordance with the German Animal Protection Law, as well as according to international animal welfare legislation and rules.
| DIO and lean mice
Mouse studies were performed in male diet-induced obese C57Bl/ 6N mice or in female lean C57Bl/6N (WT) and female GLP1R and 360 minutes after compound administration.
| Indirect calorimetry
For the DIO mouse study (C57Bl/6 N mice), after body weight plateaued in mice fed a high-fat diet, mice were injected with the mouse-specific dual agonist or liraglutide at 50 μg/kg twice daily water bottle with a drinking valve attachment and availability was monitored throughout the day. Water lost from the bottle was collected in a drip tray beneath the drinking valve. Monkeys were provided with up to 5000 mL of water per day, which was added as needed between 6:00 PM and 7:00 PM, prior to the dark period. Water samples were routinely analysed for specified microorganisms and environmental contaminants. There were no known contaminants present in the diet or water that could confound the data generated in this study. Monkeys were provided with enrichment toys or devices at all times. Enrichment items were changed weekly for all study animals according to KBI SOP. Enrichment items included: plastic chew toys, plastic balls, food puzzles and foraging trays. Animals were stratified by randomized block stratification into 3 homogenous groups according to body weight, fasted plasma glucose and % HbA1c .
| Experimental design
For the DIO monkey study, animals were trained for 3 weeks to habituate them to the blood-draw procedure and for presentation of 
| Treatments
Liraglutide, a selective GLP-1R agonist, was chosen as the positive 
| Mouse-and monkey-specific dual GLP-1R/GCGR agonist peptides
In a recent publication we described the rational design of dual GLP-1/glucagon receptor agonists. 22 Because of its favourable physicochemical and metabolic stability properties, the marketed GLP-1R agonist exendin-4 was used as the starting point for the design.
Structural elements of glucagon were engineered into exendin-4, resulting in a hybrid peptide with potent dual GLP-1/glucagon receptor activity. A d-serine residue was introduced into position 2 to avoid DPP4-mediated degradation. 28 In addition, a palmitic acid had been attached at the ε-amino group of a lysine residue using a γ-glutamic acid spacer, a strategy that has been successfully proven to prolong half-life, 29 for example, in the case of liraglutide, via oligomerization and reversible albumin binding. As a result of these design activities, the "mouse dual agonist" was obtained. Subcutaneous administration of this peptide (1 mg/kg) in healthy mice showed a half-life of 3.2 hours, similar to that of liraglutide (3.6 hours) but with a lower exposure. 22 Further modifications of the peptide structure in positions 14 to 20 and 28 led to the "monkey dual agonist". Both the mouse and monkey dual agonists have a receptor activity ratio favouring the (mouse and monkey) GLP-1R. Liraglutide, developed by Novo Nordisk, is a marketed chemically modified GLP-1 analog, which carries a fatty acid sidechain in position 20, leading to a half-life of 13 hours in humans following subcutaneous injection. 30 It was used as a comparator compound for our studies. Amino acid sequences of these peptides are shown in Table 1 .
GLP-1 and glucagon were purchased from Bachem (Bubendorf, Switzerland). Liraglutide was used from a prefilled pen (Victoza, Novo
Nordisk). The mouse-and monkey-specific dual GLP-1R/GCGR agonists were prepared at Sanofi by Fmoc solid-phase synthesis and purified by reverse-phase high-performance liquid chromatography using water/acetonitrile (0.1% trifluoroacetic acid) gradients. The purified peptides were characterized by electrospray MS. For the monkey in vivo study, the peptide was transformed into its acetate salt.
| Determination of mouse and monkey GLP-1R and GCGR potency
Agonist activity of compounds at the receptors was determined by functional assays measuring cAMP response of HEK-293 cell lines stably expressing human, mouse or monkey GLP-1R or GCGR (Table 1) . Levels of cAMP produced were determined using a kit from Cisbio Corp. (cat. for the dual agonist and by ELISA for liraglutide.
| Statistical analysis
All data are presented as means AE SEM. A 1-way analysis of variance for factor treatment or 2-way analysis including factor time were used, followed by Dunnett's test for multiple comparisons vs the vehicle or the high-fat diet control group, and separately for comparison of the dual agonist and the reference liraglutide. Statistical significance was considered with P < .05. All analyses were performed using SAS (version 9.2) under HP-UX via interface software EverStat V6.0-alpha5.
3 | RESULTS
| Acute and multiple dose studies with mousespecific dual GLP-1R/GCGR agonist in mice
The simultaneous activation of GLP-1 and glucagon receptors (GCGR) was investigated in acute and chronic studies. In acute studies, the anti-diabetic effect was tested by measuring the 6-hour fed glucose profile and glucose tolerance in an intraperitoneal glucose tolerance test (ipGTT).
In the 6-hour glucose profile obtained under continuous ad libitum feeding conditions, the mouse-specific dual GLP-1R/GCGR agonist and selective GLP-1R agonist liraglutide were administered at 10, 30 or 100 μg/kg to healthy C57Bl6/N mice. Liraglutide significantly reduced blood glucose levels at 6 hours, but only at the 30 μg/kg (−13.7 AE 1.9%; P < .01) and 100 μg/kg (−26.0 AE 3.0%; P < .001) dose levels. In contrast, the dual agonist reduced glucose at all dose levels tested, reaching −25.5 AE 3.2% at 10 μg/kg, −31.0 AE 2.0% at 30 μg/kg and −36.9 AE 1.8% at 100 μg/kg after 6 hours ( Figure 1 ).
The same experimental design performed in GLP-1R −/− mice revealed a transient dose-dependent increase in glucose in dual agonisttreated mice 30 minutes after compound administration, reaching statistical relevance at 100 μg/kg (P < .001) (Figure 1 ). No significant difference in blood glucose was observed 6 hours after treatment. As expected, liraglutide treatment did not affect blood glucose in GLP-1R −/− mice.
In an ipGTT, a significant, dose-dependent improvement in glucose tolerance was observed for both drug treatment groups in C57Bl6/N mice at the lowest dose injected (10 μg/kg). However, at selected doses, liraglutide was less effective than the dual agonist, as observed for the area under the curve calculations ( Figure 2 ). 
In GLP-1R
| Chronic and multiple-dose study with monkeyspecific dual GLP-1R/GCGR agonist in obese and diabetic non-human-primates (NHPs)
We used the impact on total energy intake and the accompanying body weight loss as the major indicators of tolerability during the multiple-dose efficacy study in cynomolgus monkeys (Macaca fascicularis). To facilitate chronic treatment at the maximum tolerated dose, dose escalation was performed every third day. A monkey-specific dual GLP-1R/GCGR agonist, similar in its relative receptor-activity preference to the mouse-specific dual agonist, was compared to the selective GLP-1R agonist liraglutide (Table 1) (Table 2) . PK analysis on day 43 showed that the 40 μg/kg daily dose of liraglutide translated into~6-fold higher compound levels than the 4 μg/kg daily dose of the monkey-specific dual agonist (C max of 279 AE 51 ng/mL vs 43 AE 7 ng/mL, respectively) ( Table 3) While values varied between 300 and 1100 pg/mL over 24 hours in the vehicle-treated group, maximal levels of FGF21 for liraglutidetreated monkeys were in the range of 1300 pg/mL and, for the monkey-specific dual GLP-1R/GCGR agonist-treatment, approximately 2100 pg/mL.
The impact of treatment on β-cell function and insulin secretion was tested by ivGTT after overnight fasting of the monkeys. Baseline values were measured on day −32/−31, the impact of chronic treatment was investigated on days +46/+47. Because of the diabetic conditions of the monkeys, the t = 0 minute glucose values were in the hyperglycaemic range, and insulin values were elevated above 100 μU/mL ( Figure 9 ). The ivGTT data of vehicle-treated monkeys were stable during the study, concerning both glucose and insulin. In the compound-treated groups there were obvious differences between baseline and treatment tests for glucose, as well as for insulin measurements. In all compound-treated groups, first-phase insulin secretion was restored, and an early insulin peak was observed after i.v. glucose challenge. The most obvious results were obtained for the dual GLP-1R/GCGR agonist ( Figure 9 ). Glucose excursion was significantly decreased (AUC glucose, −26.6% AE 9.0% mean AE SEM; P < .05). Insulin secretion revealed a highly variable, but not statistically relevant, increase (individual AUC insulin varying from −39.6%
to >26 000%). Glucose excursion of liraglutide-treated monkeys showed a slight, but statistically non-significant, decrease (AUC glucose, −10.3% AE 2.4%) and, again, a highly variable, but not significant, elevation in insulin secretion (individual AUC insulin varying from −58.0% to >560%) ( Figure 9 ).
On day −25%, HbA1c measurements were performed to obtain baseline values and also on day +43 following chronic treatment.
While % HbA1c in the vehicle-treated group slightly deteriorated during the study period (increase from 6.4% AE 0.5% to 6.9% AE 0.5%) and liraglutide treatment only moderately improved % HbA1c (8.3% AE 0.6% at baseline to 7.8% AE 0.6%), a significant decrease and, therefore, improvement in % HbA1c was observed in NHPs treated with the monkey-specific dual GLP-1R/GCGR agonist ( Figure 10 ).
The baseline value of 8.0% AE 0.7% decreased to 6.1% AE 0.4% on day +43. For estimating long-term effects of treatment with dual agonists, we measured aspartate aminotransferase (AST) as a liver-specific biomarker and alanine aminotransferase (ALT) as an indicator of liver damage on day 32 of chronic treatment in DIO mice and during the run-out period on day 43 in the obese and diabetic monkey study (Table SA) . No statistically relevant change, but rather a decrease, was monitored for AST, while ALT was significantly reduced in DIO mice treated with the mouse-specific dual agonist. No impact of treatment was monitored in diabetic and obese monkeys.
| DISCUSSION
Oxyntomodulin was originally characterized as a bioactive enteroglucagon, 31 with activity at the glucagon receptor (GCGR), but was subsequently demonstrated to also have insulinotropic activity through activation of the GLP-1 receptor (GLP-1R). 32 Oxyntomodulin is generated by intestinal L-cells, as well as by brainstem neurons, from posttranslational processing of the preproglucagon peptide. 33 Subsequent clinical studies of oxyntomodulin demonstrated significant efficacy concerning weight loss, resulting from the combined reduction of energy intake and increase of energy expenditure.
11,16
As natural gastrointestinal hormones such as GLP-1, glucagon or oxy- 
| Contribution of energy expenditure to beneficial body weight control
An increase in energy expenditure leading to a beneficial impact on reduction in body weight in humans remains controversial. We Co-infusion of native glucagon and GLP-1 revealed that beneficial effects on food consumption, body weight and glucose control could be achieved, compared to treatment with mono-agonists. 17, 18 It was further shown that resting energy expenditure was not affected by GLP-1 infusion alone, but rose significantly when human volunteers were treated with glucagon alone and, to a similar extent, in combination with GLP-1. The increase of REE in both liraglutide-and dual GLP-1R/GCGR agonist-treated mice in the current study presumably implies a higher relative metabolic contribution of lean mass and metabolically active organs as well as increased heat loss through a relatively greater surface area. Whether this is specific to mouse metabolism or could be translated into human metabolism will be a future topic for investigation.
Dakin and colleagues 15 reported that repeated twice-daily intracerebroventricular (ICV) administration of oxyntomodulin for 7 days caused an inhibition of food intake in rats. Treated animals gained less weight than controls, but exhibited increased core body temperature, suggesting enhanced energy expenditure. This hyperthermic reaction was maintained throughout the entire study period. A concomitant pair-fed group exhibited a significant hypothermic response compared to saline-injected ad libitum-fed controls. Our measurements, covering the acute impact of treatment up to chronic effects with switching metabolism, confirm these data. As a result of continued GCGR stimulation, the mouse-specific acute adaptation of metabolism for energy saving and homeostasis changes to hypermetabolism, leading to a negative energy balance and greater body weight loss. NHPs. Nevertheless, it has been unequivocally shown that oxyntomodulin, the endogenous dual GLP-1R/GCGR agonist, reduces energy intake and body weight in overweight and obese human subjects. A pre-prandial 3-times daily injection of oxyntomodulin over a four-day period increased energy expenditure while reducing energy intake. 15 Also, co-administration of a GLP-1 agonist with a glucagon infusion resulted in an increase of energy expenditure in humans. 16 But these human studies infused GCG for only 45 to 210 minutes. A recently published study investigated whether sustained hyperglucagonaemia affects energy expenditure and hepatic glucose production in humans. 43 While no difference in RER, carbohydrate or fat oxidation could be measured, GCG-induced stimulation of energy expenditure was sustained for a minimum of 12 hours. However, the extent of increase in response to the dose of GCG used was of only marginal significance, and was of longer duration when insulin secretion was inhibited by somatostatin. Serum FGF21 levels were suppressed even during GCG infusion, indicating that circulating FGF21 was not involved in the increased energy expenditure. Our findings in diabetic and obese monkeys support this result and are in conflict with previous studies, 44, 45 indicating that GCG administration significantly increased plasma FGF21 concentration and that glucagon is a required factor for FGF21 synthesis. 46 However, whether the physiological switch of endogenous nutrient utilization observed in mice translates to humans, and whether this correlates with the circulating are, rather, a consequence of an acute negative energy balance is at present unclear. Therefore, in the absence of available data concerning energy expenditure, the search for a specific GCGR-induced biomarker in mice and non-human primates continues.
Our results from the DIO mice studies on body weight with a mouse-specific dual GLP-1R/GCGR agonist do not result exclusively from reduced food intake. We propose that our observations regarding a mechanism-related switch of substrate oxidation can be of further therapeutic benefit, and might explain the superior effect of dual GLP-1R/GCGR agonists for body weight and glucose control in obese and diabetic patients.
